Zacks Investment Research has recently initiated coverage of Atrion Corporation (ATRI) with a Neutral recommendation. The research report on Atrion, a Texas-based developer and manufacturer of medical devices, provides an in-depth analysis of the company’s financial health, market opportunities and potential risks, aiming to offer investors a balanced perspective on the stock.Atrion reported an 18.4% increase in revenue for Q1 2024, reaching $47.3 million. This growth was driven by a notable 27.8% year-over ...